Search All UT System Experts

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

L. Meneghini, A. Doshi, D. Gouet, T. Vilsbøll, K. Begtrup, P. Őrsy, M. F. Ranthe, I. Lingvay

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin'. Together they form a unique fingerprint.

Medicine & Life Sciences